Free Trial
NASDAQ:MGRM

Monogram Orthopaedics Q3 2025 Earnings Report

Monogram Orthopaedics logo
$6.00 0.00 (0.00%)
As of 10/7/2025

Monogram Orthopaedics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.10
Beat/Miss
N/A
One Year Ago EPS
N/A

Monogram Orthopaedics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Monogram Orthopaedics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, November 18, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Monogram Orthopaedics Earnings Headlines

Monogram Orthopaedics Faces Merger Review Delay
Tesla to LEAVE the car market?
Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corporate history. Tesla insiders are preparing for a dramatic new product launch – not driverless cars – that could change everything. You're running out of time to prepare.tc pixel
Monogram Orthopaedics Delays 10-Q Filing
Monogram Orthopaedics Updates on Zimmer Biomet Acquisition
See More Monogram Orthopaedics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Monogram Orthopaedics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monogram Orthopaedics and other key companies, straight to your email.

About Monogram Orthopaedics

Monogram Orthopaedics (NASDAQ:MGRM), traded on Nasdaq under the ticker MGRM, is a commercial-stage medical device company focused on developing and delivering personalized knee replacement solutions. The company’s mission centers on improving patient outcomes in knee arthroplasty by leveraging advanced design and manufacturing methods to tailor implants and instrumentation to each individual’s unique anatomy.

At the core of Monogram’s offering is the Monogram Knee System, which combines proprietary imaging software with additive manufacturing techniques to produce patient-specific implants and surgical instruments. Preoperative MRI or CT scans are used to create a three-dimensional model of the patient’s knee, allowing the system to optimize implant geometry, alignment guides, and cutting blocks. This customized approach aims to enhance implant fit, reduce surgical times, and potentially improve post-operative function and comfort.

Founded in 2018 and headquartered in Menlo Park, California, Monogram Orthopaedics has secured FDA 510(k) clearance for its partial knee replacement system and completed its first commercial cases in leading U.S. orthopedic centers. The company continues to expand its commercial footprint across the United States, with plans to pursue additional regulatory approvals and market entry in select international regions.

View Monogram Orthopaedics Profile

More Earnings Resources from MarketBeat